You are currently viewing a new version of our website. To view the old version click .

Sclerosis, Volume 3, Issue 4

December 2025 - 10 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (10)

  • Systematic Review
  • Open Access
62 Views
18 Pages

16 December 2025

Background: Although multiple sclerosis (MS)-associated tremor and ataxia are well described in the neurological literature, other extrapyramidal movement disorders (MDs), including Holmes tremor, dystonia, chorea, myoclonus, parkinsonism, and restle...

  • Systematic Review
  • Open Access
164 Views
11 Pages

Risk Factors for Relapses in Multiple Sclerosis Beyond Disease-Modifying Therapy: An Umbrella Review of Systematic Reviews and Meta-Analyses

  • Sara Terrim,
  • Samira Luisa Apostolos-Pereira,
  • Thiago Ivan Vilchez Santillan,
  • Tarso Adoni,
  • Dagoberto Callegaro and
  • Guilherme Diogo Silva

10 December 2025

Background/Objectives: People with MS continue to experience relapses despite the use of disease-modifying therapies. This has motivated growing interest in the potential of non-pharmacological factors to reduce relapse risk. However, previous studie...

  • Review
  • Open Access
620 Views
16 Pages

Recent Advances in Localized Scleroderma

  • Toshiya Takahashi,
  • Takehiro Takahashi and
  • Yoshihide Asano

2 December 2025

Localized scleroderma (LSc), or morphea, is an autoimmune connective tissue disease causing inflammation and fibrosis of the skin and underlying tissues. While distinct from systemic sclerosis, its clinical presentation is highly diverse. This review...

  • Article
  • Open Access
233 Views
12 Pages

Cognitive Impairment Screening in Multiple Sclerosis Using CoGeval: Clinical and Functional Predictors in a Mexican Cohort

  • Luis F. Hernández Salomón,
  • José A. Mejía Chávez,
  • Diana M. S. Sánchez Galván and
  • Luis E. Zapata Mercado

29 November 2025

Background/Objectives: Cognitive impairment is frequent in multiple sclerosis, yet routine screening is inconsistently implemented. We aimed to characterize cognitive impairment using CogEval in a Mexican cohort and to identify clinical and functiona...

  • Article
  • Open Access
247 Views
24 Pages

Fingolimod and Neuroinflammation in MS: Representing CD8+ T-Cell Dynamics Through Mathematical Modeling and Clinical Evidence

  • Gabriela M. Gazola,
  • João Víctor Costa de Oliveira,
  • Matheus A. M. de Paula,
  • Barbara M. Quintela and
  • Marcelo Lobosco

28 November 2025

Background: Multiple sclerosis (MS), a debilitating chronic disease of the central nervous system, is characterized by both inflammatory and neurodegenerative processes that lead to demyelination and neuronal damage. While MS remains incurable, thera...

  • Article
  • Open Access
397 Views
13 Pages

Exploring the Links Between Ankylosing Spondylitis and Amyotrophic Lateral Sclerosis: A Bidirectional Mendelian Randomization Study

  • Adeyemi Timothy Akinade,
  • Ezekiel Damilare Jacobs,
  • Chucks Marvellous Obere,
  • Victor Omeiza Ogaji,
  • Emmanuel Alakunle and
  • Olaitan I. Awe

16 November 2025

Background: Very few case reports have explored a potential link between ankylosing spondylitis (AS), an autoimmune disorder, and amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative condition. We aimed to investigate whether genetic...

  • Article
  • Open Access
364 Views
12 Pages

6 November 2025

Background: Multiple sclerosis (MS) leads to early retirement in one-third of patients. The aim of this study is to analyze the difficulties at work and to collect suggestions for support measures at the workplace to maintain the ability to work for...

  • Article
  • Open Access
558 Views
13 Pages

28 October 2025

Background: There is varied practice with Disease-Modifying Treatment (DMT) for Multiple Sclerosis worldwide. We evaluated early DMT initiation within a real-world population for long-term outcomes. Method: The Scottish Multiple Sclerosis Register (S...

  • Communication
  • Open Access
479 Views
8 Pages

Possible Reasons for the Suboptimal Response of the Cladribine Course in Daily Practice: An Independent Analysis of Data from 12 Russian Clinics and the Results of Post-Registration Studies in Other Countries

  • Alexey N. Boyko,
  • Valentina M. Alifirova,
  • Daria V. Pashkovskaya,
  • Ekaterina I. Kuchina,
  • Stella A. Sivertseva,
  • Elena L. Turova,
  • Zoya A. Goncharova,
  • Olga Yu Rudenko,
  • Yulia Yu Pogrebnova and
  • Farid A. Khabirov
  • + 9 authors

24 October 2025

Objectives: The purpose of this study was to analyze the effect of daily intake of cladribine tablets on the course of multiple sclerosis (MS) while monitoring for 1–4 years during and after the course in several neurological clinics from diffe...

  • Review
  • Open Access
1,128 Views
28 Pages

24 October 2025

Chalcones, a class of flavonoid compounds, are recognized for their unique biological properties, and especially for their antithrombotic, anti-inflammatory, and antioxidant health-promoting properties against inflammation-related disorders. Chalcone...

Get Alerted

Add your email address to receive forthcoming issues of this journal.

XFacebookLinkedIn
Sclerosis - ISSN 2813-3064